Evidence map›Paper›PMID 23065524›Full record

ArticleHaematologica2013

The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder.

Daan Dierickx, Thomas Tousseyn, Annelies Requilé, Raf Verscuren, Xavier Sagaert, Julie Morscio, Iwona Wlodarska, An Herreman, Dirk Kuypers, Johan Van Cleemput and 8 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Imaging of cystic fibrosis manifestations in the abdomen.Abdominal radiology (New York) · 2025
    Review
  3. Article
  4. The role ofQuantitative imaging in medicine and surgery · 2024
    Article
  5. Review
  6. Clinical Utility ofJournal of imaging · 2023
    Article
  7. Frontiers in medicine · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. European journal of nuclear medicine and molecular imaging · 2020
    Article
  15. Article
  16. Diagnostic Performance ofDiagnostics (Basel, Switzerland) · 2020
    Review
  17. Review
  18. Review
  19. Article
  20. Nuclear medicine and molecular imaging · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Daan DierickxDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium. Daan.Dierickx@uzleuven.be
Thomas Tousseyn
Annelies Requilé
Raf Verscuren
Xavier Sagaert
Julie Morscio
Iwona Wlodarska
An Herreman
Dirk Kuypers
Johan Van Cleemput
Frederik Nevens
Lieven Dupont
Anne Uyttebroeck
Jacques Pirenne
Christiane De Wolf-Peeters
Gregor Verhoef
Lieselot Brepoels
Olivier Gheysens
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-fluorodeoxyglucose-positron emission tomography in 170 cases with suspected or biopsy-proven posttransplant lymphoproliferative disorder. All solid organ and hematopoietic stem cell transplant recipients who underwent an 18F-fluorodeoxyglucose-positron emission tomography scan between 2003 and 2010 in our center for the indication posttransplant lymphoproliferative disorder, were retrospectively reviewed and results were compared with tissue biopsy whenever possible. One hundred and seventy positron emission tomography scans in 150 patients were eligible for evaluation. In 45 cases, the patient had a biopsy-confirmed posttransplant lymphoproliferative disorder before positron emission tomography scanning and positron emission tomography was performed for staging purposes. In the remaining 125 cases, positron emission tomography was performed to differentiate between posttransplant lymphoproliferative disorder and other diseases. 18F-fluorodeoxyglucose-uptake was quantitatively expressed by calculation of maximum and mean standardized uptake value in the most intense lesion or, in the absence of attenuation corrected positron emission tomography scans, by comparing uptake in target lesion to liver and mediastinal uptake. We found an overall sensitivity of 89%, specificity of 89%, positive predictive value of 91% and negative predictive value of 87% for posttransplant lymphoproliferative disorder detection by 18F-fluorodeoxyglucose-positron emission tomography. In a subanalysis of the 125 scans performed for differentiating posttransplant lymphoproliferative disorder from other diseases, sensitivity, specificity, positive predictive value and negative predictive value were 90%, 89%, 85% and 93%, respectively. 18F-fluorodeoxyglucose-uptake in posttransplant lymphoproliferative disorder was generally high with a median mean and maximum standardized uptake value of 9.0 (range 2.0-18.6) and 17.4 (range 2.6-26.4). Posttransplant lymphoproliferative disorder often had an atypical presentation on positron emission tomography with high incidence of extranodal involvement. In conclusion, from these data, we can conclude that 18F-fluorodeoxyglucose-positron emission tomography is highly sensitive for detecting posttransplant lymphoproliferative disorder and has an excellent ability to differentiate posttransplant lymphoproliferative disorder from non-malignant diseases.

Indexed as

Fluorodeoxyglucose F18Positron-Emission TomographyAdultBiopsyFemaleHematopoietic Stem Cell TransplantationHumansLymphoproliferative DisordersMaleMiddle AgedOrgan TransplantationReproducibility of ResultsRetrospective StudiesSensitivity and SpecificityTime FactorsFluorodeoxyglucose F18

Identifiers

PMID23065524
PMCPMC3640123
OpenAlexW2061446569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.